Free Trial

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

→ Why I mailed a private folder to the best traders I know (From DTI) (Ad)
Free MDGL Stock Alerts
$280.16
-5.50 (-1.93%)
(As of 06/28/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends

Madrigal Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Consensus Price Target

$348.17
24.27% Upside
High Forecast$410.00
Average Forecast$348.17
Low Forecast$150.00
TypeCurrent Forecast
7/1/23 to 6/30/24		1 Month Ago
6/1/23 to 5/31/24		3 Months Ago
4/2/23 to 4/1/24		1 Year Ago
7/1/22 to 7/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$348.17$345.09$377.40$312.36
Forecasted Upside24.27% Upside38.48% Upside34.46% Upside32.30% Upside

MDGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Madrigal Pharmaceuticals Stock vs. The Competition

TypeMadrigal PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.69
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside24.27% Upside804.36% Upside11.52% Upside
News Sentiment RatingPositive News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageNeutral
6/11/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$382.00+49.87%
5/10/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Mamtani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetNeutral ➝ Neutral$270.00 ➝ $200.00-3.34%
5/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$389.00 ➝ $382.00+84.27%
5/8/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$425.00 ➝ $390.00+88.13%
5/8/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Outperform ➝ Market Outperform$397.00 ➝ $381.00+82.80%
A new way to collect income from stocks (Ad)

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.
4/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageUnderperform$150.00-29.26%
3/20/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$325.00 ➝ $405.00+56.40%
3/15/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$338.00 ➝ $377.00+30.88%
3/15/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$320.00 ➝ $375.00+30.19%
3/15/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$349.00 ➝ $390.00+35.40%
3/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$337.00 ➝ $410.00+42.34%
3/14/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$336.00+16.65%
12/20/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$145.00 ➝ $315.00+25.86%
12/20/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$129.00 ➝ $309.00+31.58%
12/19/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderperform ➝ Market Perform
12/19/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$178.00 ➝ $375.00+66.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:22 PM ET.

MDGL Forecast - Frequently Asked Questions

What is Madrigal Pharmaceuticals's stock forecast and purchase recommendation?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Madrigal Pharmaceuticals is $348.17, with a high forecast of $410.00 and a low forecast of $150.00. The consensus rating for Madrigal Pharmaceuticals stock is Moderate Buy based on the current 1 sell rating, 2 hold ratings and 10 buy ratings for MDGL. Learn more on MDGL's analyst rating history.

Do Wall Street analysts like Madrigal Pharmaceuticals more than its competitors?

Analysts like Madrigal Pharmaceuticals less than other "medical" companies. The consensus rating score for Madrigal Pharmaceuticals is 2.69 while the average consensus rating score for "medical" companies is 2.71. Learn more on how MDGL compares to other companies.

Does Madrigal Pharmaceuticals's stock price have much upside?

According to analysts, Madrigal Pharmaceuticals's stock has a predicted upside of 39.45% based on their 12-month stock forecasts.

What analysts cover Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has been rated by research analysts at B. Riley, Bank of America, Cantor Fitzgerald, Citigroup, HC Wainwright, JMP Securities, and Wolfe Research in the past 90 days.


Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MDGL) was last updated on 6/30/2024 by MarketBeat.com Staff

From Our Partners
Elon Musk: THIS will be bigger than Tesla
If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...
Paradigm Press | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
A Silent Invasion of America
The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...
The Freeport Society | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
Silver Expected for Extreme Price Action
Our newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...
Colonial Metals | Sponsored
Trump’s arrest is phase one
In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the...
Porter & Company | Sponsored
Where AI is REALLY Going Next
Buying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But...
InvestorPlace | Sponsored
Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Weiss Ratings | Sponsored